Polatuzumab vedotin and Tbo-filgrastim Subcutaneous
Determining the interaction of Polatuzumab vedotin and Tbo-filgrastim Subcutaneous and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.ADJUST DOSING INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells. MANAGEMENT: Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents. References "Product Information. Leukine (sargramostim)." Immunex Corporation, Seattle, WA. "Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA, North Wales, PA. "Product Information. Stemgen (ancestim)" Amgen, Thousand Oaks, CA. "Product Information. Neupogen (filgrastim)." Amgen, Thousand Oaks, CA. View all 4 references
Professional:ADJUST DOSING INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.
MANAGEMENT: Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.
- "Product Information. Leukine (sargramostim)." Immunex Corporation, Seattle, WA.
- "Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA, North Wales, PA.
- "Product Information. Stemgen (ancestim)" Amgen, Thousand Oaks, CA.
- "Product Information. Neupogen (filgrastim)." Amgen, Thousand Oaks, CA.
Generic Name: polatuzumab vedotin
Brand name: Polivy
Synonyms: Polatuzumab Vedotin
Generic Name: tbo-filgrastim
Brand name: Granix
Synonyms: Tbo-filgrastim
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Polatuzumab vedotin-Tcis
- Polatuzumab vedotin-TDVAX
- Polatuzumab vedotin-TE Anatoxal Berna
- Polatuzumab vedotin-Tecentriq
- Polatuzumab vedotin-Tecfidera
- Polatuzumab vedotin-Technescan HDP
- Tbo-filgrastim Subcutaneous-Polatuzumab Vedotin-piiq
- Tbo-filgrastim Subcutaneous-Polio vaccine, inactivated
- Tbo-filgrastim Subcutaneous-Poliovirus Vaccine (Inactivated)
- Tbo-filgrastim Subcutaneous-Poliovirus vaccine, inactivated Injection
- Tbo-filgrastim Subcutaneous-Polivy
- Tbo-filgrastim Subcutaneous-Polmon